Why should we need the gut microbiota to respond to cancer therapies?

Sophie Viaud, Romain Daillère, Takahiro Yamazaki, Patricia Lepage, Ivo Boneca, Romina Goldszmid, Giorgio Trinchieri, Laurence Zitvogel

    Research output: Contribution to journalArticlepeer-review

    17 Citations (Scopus)

    Abstract

    Cyclophosphamide, one of the most efficient tumoricidal, antiangiogenic, and immunostimulatory drugs employed to date mediates part of its effects through intestinal bacteria, against which the host becomes immunized during treatment. Our recent work suggests that anti-commensal effector pTH17 and memory TH1 CD4+ T-cell responses are indispensable for optimal anticancer effects as mediated by cyclophosphamide.

    Original languageEnglish
    Article numbere27574
    JournalOncoImmunology
    Volume3
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2014

    Keywords

    • Antibiotics
    • Cancer
    • Chemotherapy
    • Gram-positive bacteria
    • Immunomodulatory regimen
    • Microbiota
    • PTh17

    Cite this